Anterix officer exercises 40K options, sells 23K
Anterix Inc. (ATEX) reported that Chief Reg & Comm Officer Christopher Guttman-McCabe exercised a stock option for 40,000 shares of common stock at an exercise price of $37.42 per share.
Rhea-AI Filing Summary
Anterix Inc. (ATEX) reported that Chief Reg & Comm Officer Christopher Guttman-McCabe exercised a stock option for 40,000 shares of common stock at an exercise price of $37.42 per share. The option was fully vested. The exercise was paid on a cashless basis, with the issuer withholding 16,561 shares to cover the exercise price and related income tax withholding and remittance obligations. On the same date, the reporting person sold an aggregate of 23,439 shares of common stock in open-market transactions at weighted average prices ranging from about $94.22 to $90.06 per share. The transactions were not reported as being made pursuant to a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F6 | 40,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 40,000 | $34.72 | $1.39M |
| Exercise Price or Tax Liability | Common Stock F1 | 16,561 | $90.38 | $1.50M |
| Sale | Common Stock F2 | 5,372 | $93.5863 | $503K |
| Sale | Common Stock F3 | 7,791 | $92.7691 | $723K |
| Sale | Common Stock F4 | 7,580 | $91.6945 | $695K |
| Sale | Common Stock F5 | 2,696 | $90.6095 | $244K |
Footnotes (6)
- F1. The Reporting Person exercised a stock option to purchase 40,000 shares of the Issuer's Common Stock for $37.42 per share and paid the exercise price on a cashless basis, resulting in the Issuer withholding an aggregate of 16,561 shares of the Issuer's Common Stock subject to the stock option to pay the exercise price and to satisfy its income tax withholding and remittance obligations in connection with the exercise of the stock option. The withholding of shares referenced here does not involve an open market sale of stock.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.215 to $93.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.265 to $92.265, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.205 to $91.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.01 to $90.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F6. The option shares are fully vested.
Key Figures
Key Terms
cashless basis financial
weighted average price financial
income tax withholding and remittance obligations financial
FAQ
What did ATEX insider Christopher Guttman-McCabe report in this Form 4?
How many Anterix (ATEX) options did the insider exercise and at what price?
How were the exercise costs and taxes handled in this ATEX Form 4?
Were the reported ATEX transactions under a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.